Antengene Corporation Limited (06996.HK) Fiyatı

Antengene Corp. Ltd. operates as a clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai and currently employs 152 full-time employees. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The firm's products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.